Merus

e Optimized by GlymaxXIII Manufacturing Technology mere technology. Under the terms of the agreement, Merus has obte email growth factor reception) and Lgr5 (sucher-ich: repeat-contain why signs of anti-termor activity in patients with advanced solid termor

time, we are continuing to advance our other GlymauXI®-ena odes enhances their binding to natural killer, or NK, cells and

GlymaxX[®]

he Openal[®] micrology, analysed by Polician, powent the systemic data sugar "accourt and heary, in a solido, you have a local in a local in the one of a policy without ACCC. The Openal[®] micrology is based on the settine transmission of a local in the openal of a local in the one of a policy without heary and a local in the openal of a local in the one of a policy without ACCC. The Openal[®] micrology is based on the settine transmission of a local in the openal of a local in the openal of a local in the openal of a local interview. The Openal[®] micrology is based on the settine transmission of a local interview. The Openal[®] micrology is based on the settine transmission of a local in the openal of a local interview. The Openal[®] micrology is based on the settine transmission of a local interview. The Openal[®] micrology is based on the settine transmission of a local interview. The Openal[®] micrology is based on the settine transmission of a local interview. The Openal[®] micrology is based on the settine transmission of the settine transmission of a local interview. The Openal[®] micrology is based on the settine transmission of the settine transmission of the settine transmission of a local interview. The Openal[®] micrology is based on the settine transmission of the settine transmissio s pathway. As a unique feature, differentiating it from other approaches, Glymaax⁴⁰ can be applied to both rovel and already existing antibody prod axion platforms by modifying the host cell line. ProlikiGen others its Glymaax⁴⁰ technology royaby-free as a service or as an individual license.

Mach Publisher you and an and you want was a second of the second of the

nd the CHG heterodimerization technology for the production of full-length IgG Biclonics[®]. Then looking attainments within the meaning of the Private Securities Litigation Reform Act of 1966. All states in based on management's current expectations. These statements are relitive promises for guarantee with rights to cur technologies or bispecific antibody candidates; potential delays in regulatory approval Gen's GlymaxX[®] technology may have on our Bickonick[®] pipeline, the timing of FDA filings and the timing and anti that do not relate ics[®] platform can have on cancer, MCLA-158's potential to treat or where a stepsy with the half-ball ball ball ball ball balls and ball ball ball balls balls and ball ball ball balls ba criminal sunctions; recently enacted or hause legislation; failure to compete successfully against on m biosimilanc; our reliance on third parties to conduct our clinical train and the potential for those thi hanges in United Stanse patent law; protection of the confidentiality of our trade succes;; claims asso as as a dicibile share wild into the market: provident of our Vedes of Association or Du nd other important factors discussed under the caption 'Risk Factors' in our final prospectus filed with the Securities and Exchange Commission, or SEC, on May 20, 2016 in sum our views to change. These Soward-Socking assements should not be relied upon as representing our views as of any date subsequent to the date of this press missaw. m of the second dia inquiries for Merus:akaspionir. Ludger Wess or Ines-Regina ButhBhone: +40 40 88 16 59 64 / +40 30 2363 27688-mail: infomakaspion.com